Core Insights - Altimmune, Inc. is a biopharmaceutical company focused on liver disease treatments, immune modulating therapies, and vaccines, gaining attention due to insider activity and analyst interest [1] Group 1: Insider Activity - Director Durso Jerome Benedict purchased 12,500 shares at $4.13 each, indicating confidence in the company's future prospects [1][5] Group 2: Analyst Price Targets - Wall Street analysts have set a mean price target of $17.88 for Altimmune, suggesting a potential upside of 229.3% from its last closing price of $5.43 [2][5] - Price targets vary significantly, ranging from $1.00 to $28.00, with a standard deviation of $8.81, highlighting differing expectations among analysts [2] Group 3: Stock Performance - Altimmune's stock is currently priced at $4.14, reflecting a 6.15% increase today, with a trading range between $3.95 and $4.44 during the day [3] - Over the past year, the stock has reached a high of $8.25 and a low of $2.90, with a market capitalization of approximately $365.4 million [3] Group 4: Earnings Estimates - An upward trend in earnings estimate revisions could signal further upside for Altimmune in the near term, but the lowest analyst estimate suggests a potential decline of 81.6%, while the most optimistic forecast points to a possible 415.7% increase [4]